⌕
Cullinan Therapeutics · CGEM · Nasdaq
Tenet 55 · Mixed
Compare
$9.28−2.37%At closeTenet 55 · Mixed
$9.28−0.23 (−2.37%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Cullinan Therapeutics (CGEM) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

25 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue history is too short to read a growth trend (through FY21), net margin −356.3%. Worth your attention in FY25: Share count (+38.6%). Visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)—
0.0
no value for 1 of 5 yearsCAGR —
Net income ($M)▼31.4%
−219.9
no value for 1 of 5 yearsCAGR —
Free cash flow ($M)▼21.0%
−175.8
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+38.6%

43.1mn → 59.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−187.4R&D−54.2SG&A−241.6Op income21.8Tax & other−219.9Net income

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.0—A18,943.0——
Cost of revenue
—0.00.00.0—A0.0——
Gross profit
—0.00.00.0—A18,943.0——
Research & development
169,674.0187,402.0142,903.0148,156.0—A57,751.0▲31.1%—
Selling, general & admin
49,136.054,246.054,016.042,493.0—A29,146.0▲0.4%—
Total operating expenses
218,810.0241,648.0196,919.0190,649.0—A86,897.0▲22.7%—
Operating incomefeeds ROC rank
−218,810.0−241,648.0−196,919.0−191,089.0—A−67,954.0▼22.7%—
Other income, net
15,344.021,769.029,461.021,866.0—A469.0——
Pretax income
−203,466.0−219,879.0−167,458.0−169,223.0—A−67,485.0▼31.3%—
Income tax
—0.0117.0−14,122.0—A———
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−203,466.0−219,879.0−167,383.0−153,162.0—A−67,485.0▼31.4%—
Per share
Diluted EPSbuyback-sensitive
—A—A—A—A—A—A——
Diluted shares (mn)
64.6059.7054.4242.16—A43.08▲9.7%—
Margins
Gross margin
—————A100.0%——
Operating margin
—————A−358.7%——
Net margin
—————A−356.3%——
† TTM = trailing four quarters through 2026-09-30.A Withheld by our checks.
FY20 – FY20 · 1 more year
Unlock the full history →
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-10 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.